Budiodarone

Drug Profile

Budiodarone

Alternative Names: ATI-2042

Latest Information Update: 24 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ARYx Therapeutics
  • Developer Armetheon
  • Class Benzofurans; Class III antiarrhythmics; Small molecules
  • Mechanism of Action Calcium channel antagonists; Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atrial fibrillation; Ventricular tachycardia

Most Recent Events

  • 13 Feb 2017 Budiodarone is still in phase II trials for Atrial fibrillation in USA, Canada and European Union
  • 13 Feb 2017 Armetheon has patent protection for budiodarone in USA
  • 13 Feb 2017 Armetheon plans a phase II trial for Atrial fibrillation and Ventricular tachycardia in USA in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top